Prescription coverage is critical because Alzheimer's medicines only help when taken steadily over time, and their pharmacy and infusion bills quickly exceed what most families can pay alone. Coverage decides whether a person can start treatment promptly and stay on it long enough to protect memory and daily function. Alzheimer's disease is a progressive brain disorder that damages memory, judgment, and the ability to manage daily activities. Symptom management depends on continuous access to prescribed drugs, not single prescriptions, so gaps in coverage can interrupt care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which medicines matter for daily symptoms?
- Why do infused therapies raise the coverage stakes?
- How do drug costs strain families?
- What should families check in a drug plan?
Which medicines matter for daily symptoms?
Standard treatment includes cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, which preserve acetylcholine for memory and judgment. Memantine regulates glutamate to support reasoning and daily activities in moderate-to-severe disease, according to the National Council on Aging in its treatment overview. People often take these drugs for months or years.
Missing refills can allow confusion, agitation, and difficulty with dressing, meals, and household tasks to worsen. Newer options add another layer. Lecanemab and donanemab target amyloid in early symptomatic disease and may modestly slow early decline. They do not cure Alzheimer's and apply only to selected early-stage patients.
Why do infused therapies raise the coverage stakes?
Infused amyloid therapies are given in clinics over many months, with brain scans and monitoring visits alongside the infusions. Medicare Part B covers them only for patients with mild cognitive impairment or mild dementia plus confirmed amyloid, with physician registry participation, according to CMS in its coverage plan. That narrow eligibility makes prior confirmation of coverage especially important.
A family needs to know before scheduling infusions whether the diagnosis, amyloid test, prescriber, and facility all meet the coverage terms. Cost exposure is also higher than routine prescriptions. Leqembi's list price is about $26,500 per year, so standard 20% Part B coinsurance would leave roughly $5,300 plus scan and infusion-facility charges without supplemental coverage, as reported by GovExec in its Medicare enrollment guide.
How do drug costs strain families?
People with Alzheimer's and related dementias face sustained prescription spending across many maintenance drugs. Sleep, mood, memory, and coexisting conditions such as blood pressure or diabetes each add prescriptions. Medicare Part D now caps annual out-of-pocket spending on covered pharmacy-benefit drugs at $2,100 in 2026, up from $2,000 in 2025, after which plans pay 100% of covered costs, according to Benefits Empire reporting on CMS parameters in its Part D summary.
That cap helps with covered retail drugs once a family reaches it. It does not erase every expense. Noncovered drugs, infused-therapy coinsurance under Part B, transportation, scans, and facility charges can still accumulate outside the pharmacy cap.
What should families check in a drug plan?
Bring a complete medication list to enrollment counseling or the pharmacist review. Include dose, pharmacy, prescriber, and whether each drug is taken by mouth, patch, or infusion.
- Confirm that current memory medicines and related prescriptions are on the plan formulary at an affordable tier.
- Ask whether an infused therapy needs prior authorization, amyloid confirmation, a specific facility, and registry enrollment.
- Add up premiums, deductibles, pharmacy coinsurance, Part B coinsurance, scan charges, and infusion-facility fees.
- Check supplemental, Medigap, Medicaid, or employer coverage for Part B coinsurance and uncovered services.
